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Abstract 1 
 2 
Pseudomonas aeruginosa MPAO1 is the parental strain of the widely utilized transposon 3 
mutant collection for this important clinical pathogen. Here, we validate a model system to 4 
identify genes involved in biofilm growth and biofilm-associated antibiotic resistance.  5 
Our model employs a genomics-driven workflow to assemble the complete MPAO1 genome, 6 
identify unique and conserved genes by comparative genomics with the PAO1 reference 7 
strain and genes missed within existing assemblies by proteogenomics. Among over 200 8 
unique MPAO1 genes, we identified six general essential genes that were overlooked when 9 
mapping public Tn-seq datasets against PAO1, including an antitoxin. Genomic data were 10 
integrated with phenotypic data from an experimental workflow using a user-friendly, soft 11 
lithography-based microfluidic flow chamber for biofilm growth and a screen with the Tn-12 
mutant library in microtiter plates. The screen identified hitherto unknown genes involved in 13 
biofilm growth and antibiotic resistance. Experiments conducted with the flow chamber 14 
across three laboratories delivered reproducible data on P. aeruginosa biofilms and validated 15 
the function of both known genes and genes identified in the Tn-mutant screens.  16 
Differential protein abundance data from planktonic cells versus biofilm confirmed 17 
upregulation of candidates known to affect biofilm formation, of structural and secreted 18 
proteins of type VI secretion systems and provided proteogenomic evidence for some missed 19 
MPAO1 genes. This integrated, broadly applicable model promises to improve the 20 
mechanistic understanding of biofilm formation, antimicrobial tolerance and resistance 21 
evolution in biofilms.  22 
 23 
 24 
Keywords: Pseudomonas aeruginosa, biofilm formation, antibiotic resistance, de novo 25 
genome assembly, Tn-seq, essential genes, type VI secretion system, toxin-antitoxin 26 
systems, colistin    27 
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Introduction 1 
 2 
Pseudomonas aeruginosa is a Gram-negative bacterium ubiquitously present in soil, water 3 
and different animal hosts 1. As an opportunistic human pathogen 2 it can cause sepsis, and 4 
chronic wound and lung infections, especially in immunocompromised and cystic fibrosis 5 
patients. Two mechanisms complicate the treatment of P. aeruginosa infections. It forms 6 
recalcitrant biofilms in which the bacterial cells have an increased tolerance against 7 
antimicrobial compounds 3,4. In addition, worldwide, multiple genetic variants have acquired 8 
antimicrobial resistance (AMR) traits 5, either through acquisition of resistance genes on 9 
mobile genetic elements such as plasmids 6 or through de novo mutations of chromosomal 10 
genes 7. Furthermore, mutations affecting outer membrane porins and multi-drug efflux 11 
pumps can mediate resistance to almost all major antibiotic classes and several important 12 
biocides 8,9. P. aeruginosa thus also belongs to the notorious group of ESKAPE pathogens, 13 
which represent the leading causes of worldwide nosocomial infections (Enterococcus 14 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, P. 15 
aeruginosa, and Enterobacter species) 10,11. Clinically most relevant are the resistances of P. 16 
aeruginosa strains against fluoroquinolones, aminoglycosides and beta-lactams, and against 17 
the last-resort antibiotic colistin (a polymyxin). In 2017, the World Health Organization (WHO) 18 
classified carbapenem-resistant P. aeruginosa strains in the highest priority group of “critical 19 
pathogens”. New treatment options informed by a more detailed molecular understanding of 20 
how and why resistance emerges during treatment, and how resistance is transmitted, are 21 
urgently needed for such critical pathogens.  22 
 23 
Increased antimicrobial tolerance, a fundamental property of biofilms 12 is well-studied 13 and 24 
four mechanisms play a major role: (i) under nutrient-limited conditions in biofilms, P. 25 
aeruginosa expresses phenotypic variants, i.e., dormant cells that are less susceptible to 26 
antibiotics which target actively dividing cells 14; (ii) P. aeruginosa form a protective extra-27 
cellular matrix composed of polysaccharides, proteins and DNA that limits the diffusion of 28 
antimicrobial substances or sequesters them, such that biofilm cells experience a decreased 29 
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antimicrobial dosage 15; (iii) anoxic conditions exist within the biofilm limiting the efficacy of 1 
antibiotics that require aerobic metabolic activity and the generation of reactive oxygen 2 
species 16; (iv) sub-inhibitory concentrations of antibiotics induce increased rates of mutation, 3 
recombination and lateral gene transfer. The mutation rate in biofilms has been reported to 4 
be up to 100 times higher than in planktonic cells 17, significantly accelerating the 5 
development of antibiotic resistant mutants. Together, these mechanisms lead to hard-to-6 
treat, chronic infections during which P. aeruginosa can persist and further evolve within the 7 
host in the presence of antimicrobial substances. Evolution within biofilms is highly parallel 8 
and differs significantly from evolution of planktonic cells 18. However, the evolutionary drivers 9 
of within-biofilm AMR evolution remain poorly understood. Their study requires well-defined 10 
model systems and tools, including model strains with complete genomic background 11 
information, genetic tools and flow chambers allowing representative and reproducible 12 
growth of P. aeruginosa biofilms and deep sequencing data 18.  13 
 14 
The canonical reference model strain for P. aeruginosa is PAO1, also referred to as PAO1-15 
UW. Its complete genome sequence was published in 2000 2, which allowed many 16 
breakthrough discoveries. However, a number of closely related PAO1 strains exist that differ 17 
in their phenotypic appearances 19. These include P. aeruginosa strain MPAO1 20, the 18 
parental strain of the widely utilized transposon insertion mutant library from the University of 19 
Washington (UW) 21. Such mutant collections represent highly valuable resources to uncover 20 
new functions and condition-specific essential genes in genome-wide screens 21, for example 21 
genes relevant for resistance against certain antibiotics 22 23. They have also been used to 22 
define so-called general essential genes, i.e., genes that were identified as essential under 23 
more than one relevant growth condition 24,25. As a subset of the conserved core genes of P. 24 
aeruginosa PAO1 and PA14 were shown to exhibit differential essentiality 25, the approach to 25 
focus on those general essential genes that are furthermore conserved among key pathogen 26 
strains of a species is particularly promising 26. However, the utility of such libraries to identify 27 
gain of function mutations is limited and polar effects need to be controlled for 27. Notably, no 28 
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complete MPAO1 genome sequence was available. Improvements in next generation 1 
sequencing (NGS) technologies 28 and assembly algorithms nowadays allow researchers to 2 
readily generate complete de novo genome assemblies for most prokaryotes except a few 3 
percent of strains with highly complex repeat regions 29. Such fully resolved genomes are 4 
advantageous compared to fragmented short read-based genome assemblies that can 5 
sometimes even miss conserved core genes 30; they are an ideal basis for subsequent 6 
functional genomics and systems biology studies, and allow to identify so far missed genes 7 
in genome annotations by proteogenomics 31.  8 
 9 
Here, we set out to develop, validate and make available a model system to study the 10 
biofilm-associated adaptation to antimicrobials and AMR evolution in P. aeruginosa MPAO1. 11 
Conceptually, the model was designed to integrate genotype information with phenotypic 12 
data and to leverage the valuable genetic tools and wealth of functional genomics datasets 13 
that exist for important bacterial model organisms. Important elements include the complete 14 
MPAO1 genome sequence and the design for a standardized flow chamber based on 15 
accessible soft lithography replication in poly(dimethylsiloxane) (PDMS) that can deliver 16 
laminar flow conditions relevant to typical biofilm niches. Comparative genomics with the 17 
PAO1-UW reference strain uncovered numerous MPAO1-unique genes. Strikingly, these 18 
included 39 essential genes that had been missed so far by performing reference-based 19 
mapping of public Tn-seq datasets. Proof of principle experiments highlighted reproducible 20 
biofilm growth using the microfluidic flow chamber and identified hitherto unknown genes 21 
important for biofilm growth and biofilm-associated AMR through microtiter plate screening of 22 
the mutant library. A differential (planktonic vs. biofilm) proteomic dataset uncovered genes 23 
known to play a role in biofilm formation. Finally, a publicly available, integrated 24 
proteogenomics search database enables identification of unannotated genes in MPAO1.  25 
  26 
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Results  1 
 2 
De novo genome assembly of MPAO1  3 
 4 
The availability of a complete genome sequence is an important pre-requisite to study the 5 
phenotypic adaptation and evolution of resistance to antimicrobials in biofilms. An analysis of 6 
over 9,300 completely sequenced, publicly available bacterial genomes 29 (see Methods) 7 
listed 106 P. aeruginosa strains overall, two of which were P. aeruginosa PAO1 strains, 8 
including the PAO1 type strain (Genbank AE004091), also called PAO1-UW 2. In contrast, 9 
the only strain annotated as MPAO1, i.e. the founder strain of the transposon mutant library 10 
available from the UW 21, had been sequenced with Illumina short reads, assembled into 140 11 
contigs 32 and deposited (http://www.pseudomonas.com/strain/show?id=659; Genbank 12 
ASM24743v2) in the Pseudomonas genome DB  33. To provide an optimal basis for 13 
subsequent functional genomics and evolution studies for P. aeruginosa strain MPAO1, we 14 
thus first sequenced and de novo assembled its complete genome. Due to the genomic 15 
differences reported for MPAO1 and PAO1 20 and the fact that many of the 106 completely 16 
sequenced P. aeruginosa strains have difficult to assemble genomes with long repeat pairs 17 
in excess of 10 kilobases (kb) (38/106), so-called class III genomes 29, we used third 18 
generation long reads from Pacific Biosciences’ (PacBio) RSII platform. By relying on size-19 
selected fragments (average length 9 kb; see Methods), a single bacterial chromosome 20 
could be assembled. Additional genome polishing steps with Illumina MiSeq data (300bp, PE 21 
reads) allowed the removal of remaining homopolymer errors in the PacBio assembly 34. The 22 
final, high-quality MPAO1 genome consisted of one chromosome of 6,275,467 bp and coded 23 
for 5,926 genes (Genbank CP027857; Table 1). An overview of selected predicted genome 24 
features (see Methods) is shown in Supplementary Table 1. To facilitate data mining and 25 
comparison, we also provide an extensive annotation of all 5,799 protein-coding genes. This 26 
includes information on conserved and MPAO1-unique genes compared to PAO1, the 27 
respective reciprocal best BLAST hits, protein domains, families, Gene Ontology (GO) 28 
classification, predictions of subcellular localization, lipoproteins, secreted and described 29 
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membrane-localized proteins, as well as gene essentiality status and protein abundance data 1 
below (Supplementary Data 1). 2 
 3 
Comparative genomics of MPAO1 and PAO1 strains 4 
 5 
An alignment of our de novo assembled MPAO1 genome with that of the MPAO1/P1 strain 32 6 
revealed that overall, 42,813 bp of our complete genome sequence were missed by the 140 7 
contigs of the available fragmented Illumina assembly (Fig. 1a). This comprised 66 genes 8 
(52 protein coding genes, (CDS)) either missed completely or partially, including eight of 12 9 
rRNA genes (75%) and six of 63 tRNA genes (11%). Among the CDS, the essential gene 10 
ftsY encoding the signal recognition particle-docking protein FtsY was missing, four of eight 11 
(50%) non-ribosomal peptide synthetase (NRPS) genes, three of six (50%) filamentous 12 
hemagglutinin N-terminal domain protein coding genes and three of 10 (30%) type VI 13 
secretion system (T6SS) VgrG effector proteins (Supplementary Data 1). The analysis of the 14 
number of interrupted genes or pseudogenes also confirmed the fragmented nature of the 15 
MPAO1/P1 genome compared to the complete genomes of both our assembly and the 16 
PAO1-UW type strain (Supplementary Fig. 1). Importantly, a key study of the genotypic and 17 
phenotypic diversity of P. aeruginosa PAO1 strains recently reported 10 PAO1/MPAO1 18 
laboratory isolates as complete genomes 19. As all 10 genomes have been assembled using 19 
Illumina data into sets of contigs, strictly speaking, they are not fully assembled, closed 20 
genome sequences. Indeed, the genomes of the two MPAO1 strains in that list (PAO1-2017-21 
E, 71 contigs, whole genome shotgun (WGS) QZGA00000000 and PAO1-2017-I, 70 contigs, 22 
WGS QZGE00000000) also lacked a similar amount of genomic sequence (56.5 and 59.4 23 
kb) and number of genes (55, 62) or CDS (40, 47) respectively, compared to our complete 24 
genome (Supplementary Data 1).  25 
 26 
Next, to explore the extent of strain-specific genomic differences, we created an alignment of 27 
our de novo assembled MPAO1 genome with that of P. aeruginosa strain PAO1-UW. This 28 
analysis confirmed the major differences reported previously 20, i.e. the presence of a third 29 
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prophage region (12.8 kb, 20 genes; genome coordinates 5,241,813 - 5,254,613) in strain 1 
MPAO1 (Fig. 1b) and the absence of a ~1 kb genome fragment (leading to a pseudogene 2 
annotation for MPAO1_24940 in MPAO1). An analysis of smaller differences between the 3 
genomes confirmed the 16 SNPs reported previously 20, and identified 176 additional SNPs 4 
and INDELs between MPAO1 and PAO1 that had not been reported by Klockgether and 5 
colleagues 20 (Supplementary Data 2).  6 
Notably, while the overall number of predicted genes was close for both strains (Table 1), we 7 
observed 232 gene clusters specific to strain MPAO1 and 21 clusters specific to strain 8 
PAO1-UW (Fig. 1c), suggestive of potentially relevant differences between the strains. The 9 
annotation of the shared (core) and strain-specific (unique) gene clusters is provided in 10 
Supplementary Data 3. This analysis indicated that a sizeable set of genes were specific to 11 
the MPAO1 genome, and that mapping datasets obtained from this strain back to the PAO1-12 
UW genome could overlook important genes (see below). A gene ontology (GO) enrichment 13 
analysis of the MPAO1 unique proteins against all CDS in its genome revealed that the 14 
biological process “protein phosphorylation” was significantly enriched (p value < 0.01) with 15 
10 hits among all genes including three among the unique genes (including a DNA helicase 16 
and 2 serine/threonine protein kinases; Supplementary Table 2). Furthermore, for the 17 
biological process “Bacteriocin immunity” five hits were found among all genes, two of which 18 
were among the unique MPAO1 genes (Supplementary Table 2). 19 
 20 
Tn-seq data mapping  21 
 22 
The complete MPAO1 genome sequence allowed us to re-analyze public Tn-seq datasets 23 
without the limitation of any remaining “genomic blind spots” that otherwise might preclude 24 
an identification of all essential genes 26, and the drawbacks of mapping Tn-seq data to a 25 
closely related reference genome. A re-mapping of MPAO1 Tn-seq datasets obtained from 26 
several conditions (LB medium, minimal medium, sputum and brain-heart infusion BHI 27 
medium) 24 against both the PAO1-UW genome and our MPAO1 genome (see Methods), 28 
confirmed our expectation. We indeed observed a higher percentage of mapped reads for 29 
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MPAO1 (roughly 0.1 - 0.35% of all mapped reads per sample; Supplementary Table 3) and 1 
unique insertion sites (roughly 0.2% more in MPAO1, Supplementary Table 3). Genes with 2 
no insertion or genes whose p value was less than 0.001 were considered essential (see 3 
Methods). Overall, 577 genes were classified as condition-specific essential in one of the 4 
three primary growth conditions LB medium, minimal medium, sputum (Supplementary Data 5 
4), and 312 genes represented general essential genes, i.e., were essential in all three 6 
growth conditions, respectively (Supplementary Fig. 2). Importantly, close to 40 MPAO-1 7 
unique genes were linked here with an essentiality status, as they were essential in one or 8 
more of the 16 Tn-seq libraries (Supplementary Data 4). By mapping data against the PAO1-9 
UW genome, these genes had been previously overlooked in the analysis of essential P. 10 
aeruginosa genes.  11 
Among these MPAO1-unique genes, we identified 18 genes that were essential in 50% or 12 
more of the Tn-seq runs, six of which represented general essential genes (Table 2). The 13 
general essential genes included two genes located in the prophage2 region, i.e., 14 
MPAO1_22380, a type II Phd/YefM family antitoxin gene located next to MPAO1_22375, 15 
coding for a RelE/ParE type toxin, and MPAO1_22450, a DNA-binding protein (Fig. 2a; 16 
arrows framed in red). A further general essential gene was MPAO1_00215 encoding for a 17 
hypothetical protein. MPAO1_00215 is located in a genomic region that harbors another 18 
essential gene (MPAO1_00230, Supplementary Data 1), that may represent an operon.  19 
Furthermore, the prophage 3 region unique to strain MPAO1, harbored a gene encoding a 20 
hypothetical protein (MPAO1_24865; Fig. 2b) that was essential in eight of 16 samples 21 
(Table 2). Conversely, MPAO1_24885 (addiction module antidote protein from the HigA 22 
family toxin-antitoxin (TA) system) from this region was classified as general essential (Table 23 
2; 14 of 16 samples). Due to its homology to PA4674 in PAO1-UW, which is listed among the 24 
352 general essential genes reported by Lee and colleagues and encodes the HigA antitoxin 25 
24, it is not unique to MPAO1 (Fig. 2b). Together with the non-essential MPAO1_24890 26 
(plasmid maintenance system killer protein; most similar to RelE-like toxins of the type II TA 27 
system HigB), MPAO1_24885 encodes for a TA system. However, there is no homolog 28 
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annotated for MPAO1_24890 in PAO1-UW. Therefore, due to this missing gene, the TA 1 
system was not identified in PAO1-UW. This finding again underlines the importance of 2 
having the actual and complete genome sequence to map functional data. 3 
 4 
Reproducible formation of MPAO1 biofilms 5 
 6 
The second important objective of our integrated model system was to enable the reliable 7 
generation of phenotypic data under conditions relevant for biofilm-growth. For this purpose, 8 
we focused on the development of a microfluidic flow chamber for reproducible biofilm 9 
formation that would allow us to subsequently identify genes relevant for biofilm growth and 10 
biofilm-associated AMR. The flow chamber was designed in such a way that we could 11 
assess the effects of hydrodynamic conditions 35, such as shear stress and controlled flow 12 
conditions. Our flow chamber was replicated in PDMS, a simple to use, transparent and 13 
breathable elastomer material that naturally adheres to glass. A straight microfluidic channel 14 
design was used (30 mm length x 2 mm width x 0.200 mm depth) (Fig. 3a, see Methods for 15 
further details). PDMS was selected due to its broad application in indwelling devices and 16 
implant materials 36. The inlet and outlet of the microfluidic flow chamber comprised of sterile 17 
polytetrafluoroethylene (PTFE) tubing, a material that was chosen because it generally 18 
exhibits low bacterial adhesion. A syringe pump was used to deliver 5 μL/min (ū≈208 µm/s) 19 
flow inside the chamber to provide laminar flow conditions for bacterial adhesion and biofilm 20 
growth (the calculated Reynolds Number corrected for transport of water at 37 °C was 0.103; 21 
for details see Supplementary Table 4). 22 
The reproducibility of a 72 h mature MPAO1 biofilm on the PDMS surface of the device was 23 
investigated by confocal laser scanning microscopy (CLSM) combined with live/dead staining 24 
using the dyes Syto9 and propidium iodide in three separate consortium laboratories all 25 
using the same microfluidic chamber mold (design publicly available; see Data Access) (Fig. 26 
3b, c). The biofilms formed in the three laboratories were consistent with data falling within 27 
95% confidence intervals, the only difference being the observation of a reduced dead 28 
biovolume in one laboratory’s model (Lab A; p value < 0.05). Biofilm formation was relatively 29 
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uniform throughout the flow channel with an average thickness of 16 µm and a small 1 
reduction observed towards the center of the channel (Inlet - 18.8 µm, 25% - 15.8 µm, 50% - 2 
13.3 µm, 75% - 14.9 µm, Outlet - 17.3 µm). An average biovolume of 12.5 µm3/µm2 and dead 3 
biovolume of 8.4 µm3/μm2 was observed, again reducing towards the center of the device 4 
commensurate with the average biomass.  5 
 6 
Screening experiments identify known and new genes relevant for biofilm 7 
formation and antibiotic resistance  8 
 9 
The MPAO1 transposon mutant library was tested with a 96-well plate screening system that 10 
was devised to enable the identification of genes that affect biofilm formation and/or play a 11 
role in the development of biofilm-associated AMR (see Supplementary Fig. 3). A batch of 95 12 
selected mutants (see Supplementary Table 5) was taken from the library to test the 13 
reliability of our protocol and to identify genes related to biofilm formation (in duplicate). 14 
Strain PW8965 harboring an insertion in cbrB (PAO1 identifier PA4726, MPAO1_25185), a 15 
transcriptional activator that forms part of the CbrA/CbrB two-component system important in 16 
catabolite repression 37, was found to produce the least amount of biofilm (Fig. 4a). In 17 
contrast, strain PW9283 mutated in pntAA (PA0195; MPAO1_01040), a NADPH/NAD+ redox 18 
balance transhydrogenase 38, exhibited the highest biofilm biomass.  19 
In a second step, selected mutants identified by the screening and the proteomic analysis 20 
(see below) were compared to positive and negative controls for biofilm formation (Fig. 5a). 21 
The pslB mutant (PA2232; MPAO1_14370), a gene whose product is involved in the 22 
synthesis and export of polysaccharides, was used as a reference point for low biofilm 23 
formation 39, while a retS mutant (PA4856; MPAO1_25880), encoding a pleiotropic regulator 24 
of multiple virulence factors, was used as reference point for high biofilm formation 40. 25 
Overall, MPAO1 WT produced roughly twice the biofilm biomass of transposon mutants, 26 
suggesting that the transposon has an influence on biofilm formation and that it is more 27 
reliable to compare transposon mutants amongst each other. The transposon mutant 28 
PW7021 (an arnB mutant; PA3552; MPAO1_07345, see below) was chosen as an internal 29 
reference for biofilm formation as its biomass was found approximately midway through the 30 
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24h biofilm readings in Fig. 4a. We confirmed that the cbrB mutant produced significantly 1 
less biofilm biomass (p value < 0.001) than the arnB mutant, similar to the low biofilm forming 2 
pslB mutant. Biofilm growth of the cbrB mutant was also performed within the flow chamber 3 
to confirm the capacity of the device to assess differential biofilm formation. Similar to the 96-4 
well plate screening assay, the cbrB mutant produced substantially less biofilm compared to 5 
the MPAO1 WT over 18 h in the flow chamber (Fig. 5c) and displayed a delayed exponential 6 
growth compared to WT and the other mutants tested (Supplementary Fig. 4). We also 7 
confirmed that the pntAA mutant produced higher biofilm biomass than other transposon 8 
mutants, similar to the high biofilm former retS mutant (Fig. 5a). However, compared to the 9 
WT, the retS mutant produced comparable biofilm biomass, which is likely caused by a 10 
decrease of strain fitness due to the transposon insertion. An alternative explanation is that 11 
the effect of RetS cannot be measured after 24 h because it has been shown previously that 12 
RetS turns non-functional in P. aeruginosa WT after 8h following initial attachment 41. Genes 13 
identified by the proteomic analysis (vgrG1b, cdrA, aprX; see result section below) did not 14 
seem to affect the biofilm formation of MPAO1 in the conditions tested. 15 
Next, we tested the strains for their biofilm resistance to colistin and included the arnB 16 
mutant strain PW7021 as a positive control (see Supplementary Fig. 3). ArnB is a well-17 
studied protein known to modify lipopolysaccharide (LPS) and play a key role in the 18 
resistance to colistin 42,43. The recovery of biofilm cells after treatment with 25 µg/mL colistin 19 
was compared to the recovery of non-treated biofilm cells (Fig. 4b) (see Methods), as 20 
described previously 13. This concentration of colistin was much higher than the minimal 21 
inhibitory concentration (MIC) used for the planktonic P. aeruginosa MPAO1 (8 µg/mL) 22 
allowing us to focus specifically on biofilm cells. As expected, the arnB mutant exhibited a 23 
very low recovery after colistin treatment (97% less than the control without colistin) (Fig. 24 
4b). In contrast, the arnB mutant produced robust biofilms in the biofilm screening assay 25 
(Fig. 4a), a phenotype that was confirmed using the microfluidic chamber (Fig. 4c). Notably, 26 
the cbrB mutant strain grown as a biofilm was also found to be sensitive to colistin (90% less 27 
recovery than the control without colistin; Fig. 4a), which might be related with the low 28 
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amount of biofilm produced by this mutant. In contrast, the high biofilm former pntAA mutant 1 
exhibited high resistance towards colistin with a recovery close to the non-treated biofilm. 2 
In a second step, the resistance profile of the identified mutants was characterized in more 3 
detail by measuring the MIC of planktonic cells and the minimal biofilm inhibitory 4 
concentration (MBIC) towards colistin (Fig. 5b). Two independent experiments (with four 5 
replicates in total) confirmed the significantly higher sensitivity of planktonic cells of arnB and 6 
cbrB mutants compared to the WT (Fig. 5b). Additionally, inactivation of the genes arnB and 7 
cbrB reduced the biofilm recovery by 50% when 6 and 12 times less colistin was used, 8 
respectively, compared to the WT. Inactivating cbrB made MPAO1 biofilms more sensitive to 9 
low concentrations of colistin, but high concentrations seemed necessary to reach complete 10 
eradication (Fig. 5b). In contrast, inactivating pntAA increased P. aeruginosa resistance 11 
towards colistin both as planktonic and biofilm cells. Characterization of the genes identified 12 
in the proteomic study (see below) revealed that inactivating cdrA had no impact on MPAO1 13 
resistance, but inactivation of vgrG1b 44 and aprX 45 increased MPAO1 resistance towards 14 
colistin both for planktonic and biofilm cells (Fig. 5b).  15 
 16 
Protein abundance profiling of MPAO1 grown planktonically and in biofilms 17 
 18 
To assess if we could identify proteins known to play a role in biofilm formation with the 19 
microfluidic chamber, we next generated shotgun proteomics data for MPAO1 cells grown to 20 
mid-exponential planktonic phase or as 72 h biofilms (3 replicates each). 1,530 and 1,728 21 
proteins were identified in planktonic cells and biofilm, respectively, resulting in a combined 22 
1,922 of the 5,799 annotated proteins (33.1%). Among the most significantly differentially 23 
abundant proteins (log2 fold change (FC) of ≥ 1 or ≤ -1 and adjusted p value ≤ 0.05; see 24 
Methods and Supplementary Fig. 5) several candidates were identified that have previously 25 
been linked with a role in biofilm formation. These included MuiA (MPAO1_18330) 46, CbpD 26 
(MPAO1_21730) 47, AcnA (MPAO1_17965) 48 and PilY1 (MPAO1_24155) 49 (Fig. 5a, Table 27 
3; see Discussion). In addition, MPAO1_19625 was highly upregulated in biofilms (Fig. 5a). 28 
Notably, its PAO1 homolog AprX was reported to be secreted by a type I secretion system 45, 29 
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indicating that hypothetical proteins or proteins of unknown function can be linked to roles in 1 
biofilm formation and growth. We next looked for protein expression evidence for CDS 2 
missed in the fragmented short read genome assemblies. We found that 21 of the 52 CDSs 3 
missed in the MPAO1/P1 assembly were detected at the protein level (Supplementary Data 4 
1). Notably, this included two proteins significantly upregulated in the biofilm, namely 5 
MPAO1_00520 (T6SS tip protein VgrG1b) located close to the H1-T6SS cluster 44 and 6 
MPAO1_24535 (Fig. 5a), the homolog of PAO1 CdrA, a cylic-di-GMP-regulated adhesin 7 
known to reinforce the biofilm matrix 50, again underlining the importance of a complete 8 
genome sequence for downstream functional genomics analyses. Notably, nine of 14 9 
structural genes of H1-T6SS, one of overall three T6SSs in P. aeruginosa that helps it to 10 
prevail under stressful conditions 51, were upregulated around two-fold or more in biofilm 11 
(Supplementary Fig. 6). Similarly, all three VgrG1 proteins (1a-1c) that are co-regulated with 12 
the H1-TS66 52 were upregulated in biofilm, while none of the other seven VgrG family 13 
members were expressed. Among the proteins down-regulated in 72h biofilms, three are 14 
associated with iron acquisition; isochorismate synthase (MPAO1_03800), a rate-limiting 15 
enzyme involved in the production of salicylate (precursor of the siderophore pyochelin) 53, 16 
the siderophore receptor MPAO1_23930 (PuiA), and the siderophore-interacting protein 17 
MPAO1_15475. Iron acquisition is deemed necessary for P. aeruginosa biofilm formation 54 18 
so their down-regulation was unexpected, however, this response is likely circumvented by 19 
the utilization of alternative iron acquisition strategies including the high-affinity siderophore 20 
pyoverdine.  21 
Finally, to identify unannotated short ORFs that may carry out important functions or new 22 
start sites, we created an integrated proteogenomics search database (iPtgxDB) for strain 23 
MPAO1 and PAO1 (Supplementary Table 6), which covers its entire coding potential 31. A 24 
search combined with stringent result filtering (see Methods) allowed us to identify 25 
unambiguous peptide evidence 55 for a 44 aa longer proteoform of MPAO1_08365 (predicted 26 
by Prodigal, an ab initio gene prediction algorithm; Fig. 5b). In addition, we obtained 27 
proteogenomic evidence supporting a single nucleotide insertion in MPAO1_25975 in strain 28 
14 
 
MPAO1 as compared to PA4875 (annotated as pseudogene) in strain PAO1 (Fig. 5c). The 1 
peptide that supported this single nucleotide change at the amino acid level was identified 2 
with seven peptide spectrum matches (PSMs), illustrating the ability to identify SNP changes 3 
at the protein level, with implications for clinical proteomics. 4 
  5 
 6 
Discussion  7 
 8 
P. aeruginosa is a member of the ESKAPE pathogens, the lead cause of worldwide 9 
nosocomial infections 10. Along with many other clinically relevant bacteria, it can form 10 
biofilms whose emergent properties 56 include a much higher tolerance to antimicrobials. 11 
Together with the increased mutation rates in biofilm compared to planktonic cells 17, this 12 
further complicates treatment and cure of biofilm-based infections 12,13. The development of 13 
model systems allowing the study of antimicrobial tolerance mechanisms and the 14 
evolutionary dynamics that lead to AMR development in biofilms is thus of utmost priority.  15 
We here develop and validate such a model system for P. aeruginosa MPAO1 (Fig. 6). 16 
Conceptually, the model was designed to integrate genotype data with phenotypic 17 
information and to leverage the wealth of existing public genetic resources and functional 18 
genomics datasets. A complete, fully resolved genome sequence is one critical element 31,57, 19 
which recently allowed linking of genotypic differences of nine Pseudomonas plant 20 
microbiome isolates with their varying biocontrol potential 58. While a complete genome 21 
existed for P. aeruginosa PAO1 2, only three fragmented Illumina-based genome assemblies 22 
were available for MPAO1, the parental strain of the popular UW transposon mutant library 23 
21. These included strains MPAO1/P1 32 and the recently sequenced PAO1-2017-E and 24 
PAO1-2017-I 19. On average, they lacked between 55 to 66 genes (40 to 52 CDS) compared 25 
to our complete MPAO1 genome (Supplementary Data 1). For MPAO1/P1, these included 26 
the essential ftsY, an adhesin, several T6SS effectors (see below), and four of the overall 27 
eight NRPSs. NRPSs are highly relevant for AMR as they often represent enzymes involved 28 
in the biosynthesis of antibiotics 59. In fact, due to the multi-resistant phenotype of ESKAPE 29 
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pathogens, concerted efforts aim to describe their NRPS gene clusters in search for new 1 
therapeutic approaches 60, reinforcing the need for complete genome sequences.  2 
Comparative genomics with the PAO1 type strain uncovered an inventory of conserved and 3 
strain-specific genes, and a list of genome-wide SNPs, extending an earlier study that had 4 
compared a subset of genomic regions 20. Among the 232 MPAO1-unique gene clusters, 5 
bacteriocins 61 were enriched, which play a role in restricting the growth of closely related 6 
microbial competitors to gain an advantage in colonizing a variety of environments 62.  The 7 
complete MPAO1 genome enabled us to remap valuable existing Tn-seq datasets from 8 
relevant conditions 24, thereby identifying 39 MPAO1-unique essential genes that had 9 
escaped detection so far due to reference-based PAO1 mapping. 18 of these genes were 10 
essential in at least 50% of the 16 Tn-seq samples, and six represented general essential 11 
genes, including a Phd/YefM family type antitoxin (MPAO1_22380), which was essential in 12 
all samples. This is worth noting given the relevance of toxin-antitoxin systems for bacterial 13 
growth arrest and persistence 63. Importantly, our data do not conflict with results from 14 
previous studies; rather, they open the field to study the roles of additional MPAO1-unique 15 
essential genes. Furthermore, our results suggest that groups planning to construct 16 
inventories of core essential genes in other pathogens, following the elegant approach of 17 
Poulsen et al. who had considered both relevant media mimicking different infection types 18 
and nine strains from different lineages of a P. aeruginosa phylogenetic tree 26, should ideally 19 
select complete genomes without any genomic blind spots.  20 
 21 
To leverage the experimental arm of our model (Fig. 6), the consortium developed a PDMS 22 
microfluidic flow chamber for biofilm growth, which offers several significant advantages. It 23 
provides laminar flow conditions inside the channels (Supplementary Table 4), allows gas 24 
exchange, decreases the amount of growth medium, facilitates heat transfer, is inexpensive 25 
to replicate and permits imaging of the biofilm and easy harvesting for biochemical 26 
characterization. While the flow chamber can be used to monitor biofilm formation on both 27 
glass (oxygen impermeable) and PDMS, it is more relevant to investigate biofilm formation 28 
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on PDMS as a widely applied biomaterial used in indwelling devices and implants 36. We 1 
observed that biofilms on PDMS formed a more homogeneous layer (Fig. 3b) as compared 2 
to the commonly observed mushroom-like structures of P. aeruginosa biofilms on glass 64. 3 
This effect is not related to hydrodynamics as a flow chamber that previously has been 4 
shown to produce mushroom-like structures 65 has hydrodynamics (ū≈208 µm/s and 5 
Re=0.24) comparable to our microfluidic chip. We speculate that the effect is most likely 6 
explained by two differences: (i) PDMS is oxygen permeable and can transport oxygen to the 7 
base of the biofilm that then manifest in overall biofilm structure, or (ii) slight differences in 8 
media composition.  9 
The microfluidic data from the inter-laboratory trial on strain MPAO1 validated the utility of 10 
the flow chamber and allowed us to compare the phenotypes of WT and mutant strains of the 11 
UW transposon library. Important genes were identified with a microtiter plate screening 12 
assay and subsequently validated with the flow chamber. Proof of principle experiments 13 
confirmed the role of arnB (PA3552), i.e., a gene relevant for colistin resistance 42,43, both in 14 
biofilms grown in the 96-well plate screen and the flow chamber. In addition, a mutant lacking 15 
cbrB (PA4726) showed reduced resistance to colistin in biofilm and planktonic cells and 16 
formed very low amounts of biofilm in both the microtiter plate and flow chamber. In addition, 17 
inactivating cbrB was found to be as inhibitory for biofilm formation as inactivating the gene 18 
pslB, known to negatively influence biofilm matrix synthesis 39. As part of the two-component 19 
system CbrAB, a mutation in the response regulator cbrB is known to negatively affect the 20 
use of several carbon and nitrogen sources 37. Such a defect could explain the low growth 21 
rate, the low biofilm biomass and therefore the low resistance to colistin of this mutant. Using 22 
P. aeruginosa PA14, it was shown that a mutation in CbrA improved biofilm formation, while 23 
a mutation in CbrB did not 66. However, these differences might be explained by strains 24 
(MPAO1 versus PA14) or growth media used (M9 versus BM2-biofilm medium). In contrast, 25 
our screening revealed that inactivating the transhydrogenase pntAA induced high biofilm 26 
formation, comparable to the known gene retS. While redox balance is known to correlate 27 
with biofilm morphology 67, the precise role of pntAA remains to be investigated. Together, 28 
17 
 
the combined data of the screen and flow chamber experiments demonstrated that genes 1 
previously not implicated in AMR and biofilm formation can be identified and that the function 2 
of known genes can be validated.  3 
 4 
The differential proteomics data confirmed proteins known to play a role in biofilm formation 5 
and growth. These included MuiA, which inhibited swarming motility and enhanced biofilm 6 
formation (roles, that were validated in knockout strains) 46, and CbpD, for which higher 7 
protein abundance had been observed in late phases of biofilm growth; accordingly, mutants 8 
displayed a lower amount of biofilm growth and exopolysaccharides (EPS) 47. Similarly, for 9 
two other proteins with significantly higher abundance in biofilms, inactivation studies showed 10 
that the gene encoding AcnA impaired biofilm formation and was required for microcolony 11 
formation 48, while increased abundance of PilY1 repressed swarming and increased biofilm 12 
formation, as confirmed by knockout experiments 49. Biofilm exclusive protein expression was 13 
observed for MPAO1_00520, the T6SS VgrG1b effector protein 52, while the adhesin CdrA 14 
(MPAO1_24535) 50 was highly upregulated in biofilms. Both genes were missed in the 15 
MPAO1/P1 genome. CdrA forms a two-partner secretion system with CdrB, and both were 16 
upregulated under elevated c-di-GMP levels 50, in line with the upregulation we observed in 17 
biofilm. Moreover, an NRPS (MPAO1_14010) and the hypothetical protein MPAO1_19625 18 
were significantly upregulated in biofilm (Table 3). The data provided insights beyond the top 19 
differentially abundant proteins. Notable examples included immunity protein TplEi 68 20 
(PA1509, MPAO1_18250), a bacteriocin of the H2-T6SS 51, which was exclusively expressed 21 
in biofilm (Supplementary Data 1), and upregulation of nine of 14 structural members of H1-22 
T6SS 51 (Supplementary Fig. 6). Active T6SSs have been associated with chronic infections 23 
in cystic fibrosis patients 52, and H1-T6SS plays an important role in dominance of P. 24 
aeruginosa in multi-species biofilms 69. More sensitive and comprehensive proteomics 25 
studies are needed to overcome the limitation that only a third of the theoretical proteome 26 
was identified with our shotgun proteomics approach, e.g. by combining data dependent and 27 
data independent acquisition and the use of spectral libraries 70, allowing a more 28 
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comprehensive identification of lower abundant and small proteins, or by analyzing additional 1 
conditions or mutant strains under which tightly regulated proteins such as the Tse toxins 2 
(secreted substrates of the H1-T6SS) are expressed (Supplementary Fig. S6) 71. 3 
The public MPAO1 (and PAO1) iPtgxDBs allow to identify missed genes by proteogenomics 4 
31, which often encode short proteins (sProteins) that can carry out important functions 72,73. 5 
Interestingly, Tn-seq data from the Manoil group had implied an essential genomic region in 6 
the PF1 phage region of PAO1-UW 24. Re-mapping their data, we identified a general 7 
essential gene (MPAO1_22380) annotated in our MPAO1 genome whose homolog had been 8 
missed in the PAO1 genome annotation, and which appeared to encode the antitoxin 9 
member of a ParDE-like TA system (PA0728.1, Fig. 2). However, we did not identify 10 
expression evidence for the antitoxin MPAO1_22380 (83 aa) with our iPtgxDB, most likely 11 
because our dataset (33% of MPAO1 proteins) was not as extensive as that used in a 12 
comprehensive proteogenomic study (85% of Bartonella henselae proteins) 31, whose 13 
complete membrane proteome coverage included expression evidence for all T4SS 14 
members 74. Nevertheless, we observed proteogenomic evidence for gene products missed 15 
in the fragmented MPAO1/P1 genome, for new start sites and for single amino acid 16 
variations, underlining the potential value of proteogenomics for application in clinical 17 
proteomics.  18 
 19 
Our proof of principle experiments uncovered several candidates for follow-up studies and 20 
illustrated the benefit of the complete MPAO1 genome, which led to the discovery of six 21 
general essential genes not contained in the transposon library, and which will allow to 22 
identify evolutionary changes that lead to AMR in biofilm by deep sequencing in the future. 23 
Having been validated for the generation of reproducible inter-laboratory P. aeruginosa 24 
biofilm results, a milestone en route to a community standard (see Data Access), the 25 
microfluidic platform can be instrumental to investigate other biofilms, notably clinical 26 
pathogens and mixed-species biofilms 69. The upregulation of the H1-T6SS highly relevant 27 
for dominance of P. aeruginosa 69 implies that our microfluidic chamber should also be 28 
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valuable for this extension. Our proposed workflow (Fig. 7) with feedback between genotypic 1 
and phenotypic assessment of biofilm characteristics can thus be leveraged across the field 2 
of biofilm research and helps bridge the gap between genome-wide and reductionist 3 
approaches to study phenomena related to biofilm-associated AMR.   4 
20 
 
Methods 1 
 2 
Bacterial growth and genomic DNA extraction 3 
 4 
P. aeruginosa strain MPAO1 (originating from the lab of Dr. Barbara Iglewski) was obtained 5 
from Prof. Colin Manoil, UW (Seattle, USA) together with the transposon insertion mutant 6 
collection of ~5000 mutated genes (9437 strains) 21. For DNA extraction, the MPAO1 7 
cryoculture was streaked out on 20% BHI solid medium (7.4 g in 1 L water) containing 1.5% 8 
agar (both Sigma, Switzerland). Shaken 20% BHI fluid cultures were inoculated from a single 9 
colony and grown at 30 °C until mid-exponential phase (OD600 = 0.5). Genomic DNA 10 
(gDNA) was extracted with the GeneElute kit (Sigma, Switzerland), following the Gram-11 
negative protocol, including RNase treatment. A study that had analyzed 9331 complete 12 
bacterial genomes  29 (NCBI RefSeq, assembly category: ‘complete genome’; status Feb. 23, 13 
2018; see their TableS4) reported that 106 P. aeruginosa strains have been sequenced 14 
completely, which included only two PAO1 strains (and no complete genome of strain 15 
MPAO1). 38/106 (36%) had difficult to assemble genomes with repeat pairs greater 10 kilo 16 
base pairs (bp).  17 
 18 
Sequencing, de novo genome assembly and annotation 19 
 20 
PacBio SMRT sequencing was carried out on a RS II machine (1 SMRT cell, P6-C4 21 
chemistry). A size selection step (BluePippin) was used to enrich for fragments longer than 22 
10 kb. The PacBio run yielded 105,221 subreads (1,32 Gbp sequence data). Subreads were 23 
de novo assembled using the SMRT Analysis portal v5.1.0 and HGAP4 75, and polished with 24 
Arrow. In addition, a 2 x 300 bp paired end library (Illumina Nextera XT DNA kit) was 25 
sequenced on a MiSeq. Polishing of the assembly with Illumina reads, circularization, start 26 
alignment using dnaA and final verification of assembly completeness were performed as 27 
described previously 76. The quality of the aligned reads and the final chromosome was 28 
assessed using Qualimap 77. In addition, we checked for any potential large scale mis-29 
assemblies using Sniffles v1.0.8 78 by mapping the PacBio subreads using NGMLR v0.2.6 78. 30 
SPAdes v3.7.1 79 was run on the Illumina data to detect smaller plasmids that might have 31 
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been lost in the size selection step. The genome was annotated with the NCBI’s prokaryotic 1 
genome annotation pipeline (v3.3) 80. Prophages were identified with Phaster 81. Detailed 2 
annotations for all CDS were computed as described previously 82; this included assignment 3 
to Cluster of Orthologous Groups (COG) categories using eggnog-mapper (v 1.0.3) and 4 
EggNOG 4.5, an Interproscan analysis and prediction or /integration of subcellular 5 
localizations, lipoproteins, transmembrane helices and signal peptides (for details, see 6 
Supplementary Data 1).  7 
 8 
Comparative genomics of selected PAO1 genomes 9 
 10 
The genome of the P. aeruginosa PAO1-UW reference strain 2 was compared to our 11 
complete MPAO1 genome using the software Roary (v3.8.0) 83 to define core and strain-12 
specific gene clusters as described before 30,83. A BlastP analysis helped to correctly identify 13 
conserved genes with ribosomal slippage (prfB; peptide chain release factor B) or that 14 
encode a selenocysteine (MPAO1_25645), which otherwise can be misclassified as unique 15 
genes; genes of 120 bp or below (17 in MPAO1) were not considered. ProgressiveMauve 84 16 
was used to align the genomes globally and to identify larger genomic differences. Smaller 17 
differences (indels, single nucleotide polymorphisms (SNPs)), were identified and annotated 18 
against the PAO1 reference strain as described previously 82. Furthermore, contigs from the 19 
MPAO1/P1 genome 32 were aligned to our complete MPAO1 genome assembly using BWA 20 
mem 85. Bedtools v2.16.1 ‘genomecov’ 86 was used to calculate a gene-wise coverage, 21 
allowing to identify genes that were missed in the 140 contigs.  22 
 23 
Re-mapping of Transposon sequencing data  24 
 25 
MPAO1 Tn-seq datasets 24 were downloaded from NCBI’s SRA (SRP052838) and mapped 26 
back both to the PAO1-UW reference strain genome 2 and to our MPAO1 assembly following 27 
the scripts and notes provided in the Supplement. Insertion sites were computed as 28 
described by the authors, reads mapping to multiple genome positions were assigned 29 
randomly, and the number of insertion sites per gene was used to differentiate essential and 30 
22 
 
non-essential genes as described 24. Genes with zero insertions were considered essential; 1 
for the remaining genes, normalized read counts across all insertion sites per gene 2 
(considering insertions falling within 5-90% of the length of each gene) were log2 3 
transformed and fitted to a normal distribution. Genes with a p value < 0.001 were added to 4 
the list of essential genes. Finally, essential and conditionally essential genes were identified 5 
among the three main growth conditions (LB medium, minimal medium, sputum) as 6 
described 24. Data from each growth condition consisted of multiple mutant pools; for LB, two 7 
mutant pools additionally contained multiple replicates (LB-1: 3 replicates; LB-2: 2 8 
replicates). For LB, genes were considered essential in the mutant pool LB-1 and LB-2 if at 9 
least two of three (LB-1) and one of two replicates (LB-2) agreed. Next, a consensus set of 10 
essential genes in LB and minimal medium was derived from those genes that were 11 
essential in at least two of three mutant pools (LB-1, LB-2 and LB-3) in LB and minimal 12 
respectively. Similarly, essential genes in sputum (four mutant pools) were derived if data 13 
from at least three of four pools agreed. Finally, genes that were essential in all three growth 14 
conditions were called “general essential genes (312)” and genes essential to a specific 15 
growth condition were called “condition specific essential genes”. Together, they comprise 16 
“all essential genes (577)”; for further details, see Supplement.  17 
 18 
Microfluidic chamber used for biofilm growth 19 
 20 
The standardized microfluidic flow chamber consisted of a PDMS chip with a straight 21 
microfluidic channel (30 mm length x 2 mm width x 0.200 mm depth) that naturally adhered 22 
onto a glass coverslip (26 x 60 mm; thickness no.1). The wafer master was fabricated using 23 
SU-8 spin-coated to a thickness of 200 μm on a silicon wafer in advance of standard soft 24 
lithography replication into PDMS [84]. From this, polyurethane clones of the structures were 25 
prepared to upscale production and for sharing microfluidic molds between laboratories. A 26 
degassed 10:1 mixture of Sylgard 184 PDMS base and curing agent were cured in an oven 27 
at 60 °C for 2 h. Following cooling and retrieval from the SU-8 wafer the structured PDMS 28 
was attached, structures facing upwards, to a silicone baking mold using transparent double-29 
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sided adhesive (3M). The PDMS part was degassed, while the two-component polyurethane 1 
(Smooth-Cast™ 310) solutions were each thoroughly shaken for 10 min and then combined 2 
in a 1:1 ratio followed by thorough mixing (by repeat inversion and then shaking). The PDMS 3 
device was then submerged in the mixture, with degassing for 10 min, after which the mold 4 
was left overnight in a well ventilated area followed by a hard bake at 60 °C for 4 h. Once 5 
cooled the PDMS device was retrieved leaving the polyurethane mold in readiness for replica 6 
molding fresh PDMS devices again at 60 °C for 2 h. Importantly, PDMS devices are only 7 
retrieved after the polyurethane mold has cooled to room temperature to allow the repeated 8 
replication (> 100 times) of precision PDMS microfluidic chambers. Inlet and outlet ports 9 
were prepared using 1-mm-diameter biopsy punches (Miltex™) and then the device was 10 
enclosed using a coverslip that was cleaned with 2% RBS 35 detergent (prepared in 11 
demineralized water), rinsed with tap water, then immersed in 96% ethanol and sonicated for 12 
5 min, followed by a final rinse with demineralized water and then autoclaved. The inlet and 13 
outlet of the microfluidic flow chamber were connected to a syringe pump with a 25G needle 14 
and waste container, respectively, via sterile PTFE tubing (Smiths Medical, ID 0.38 mm, OD 15 
1.09 mm). The chamber was disinfected by flowing 70% ethanol for 15 min at a rate of 20 16 
μL/min, before rinsing with sterile PBS for 15 min and then flushing with M9 minimal medium 17 
(Formedium Ltd, Hunstanto, England) for another 15 min at the same flow rate. 18 
 19 
Device inoculation, biofilm staining and confocal laser microscopy  20 
 21 
P. aeruginosa MPAO1 was inoculated with 500 µL of an M9-grown overnight pre-culture and 22 
grown for ~16-18 h in 10 mL M9 medium (1x M9 salts supplemented with 2 mM MgSO4, 100 23 
μM CaCl2 and 5 mM glucose) at 37 °C with gentle rotation (150 rpm) until a cell 24 
concentration of 1.5 x 109 bacteria/mL was reached. One mL of the culture was then washed 25 
twice with PBS (pH 7.0) by centrifugation at 5,000 xg for 5 min at 10 °C. The bacterial pellet 26 
was re-suspended and diluted in PBS + 2% M9 such that the final cell suspension contained 27 
3 x 108 bacteria/mL. The microfluidic chamber was set on a hotplate at 37 °C with the glass 28 
coverslip in direct contact with the hotplate surface. Freshly prepared bacterial suspension 29 
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was flown through at a rate of 5 μL/min for 1 h. After 1 h, the bacterial suspension was 1 
replaced by M9 medium and run through the system at 5 μL/min for 72 h. After 72 h, CLSM 2 
images were taken. The biofilm was stained by flowing 1 mL of Live/Dead (Life 3 
Technologies, Oregon, USA) staining solution (1.5 μL Syto9 + 1.5 μL propidium iodide in 1 4 
mL of sterile demineralized water) through the flow chamber at 5 μL/min. Once the channel 5 
was filled, the flow was stopped and the biofilm kept in the dark for 30 min to allow dye 6 
penetration. Finally, PBS was flown through the system at 5 μL/min for 30 min to remove the 7 
staining agent. Confocal imaging was performed using a Leica SP8 with x63 oil immersion 8 
lens (HC PL APO CS2 63x/1.30, Southampton; LabA), a Leica SP8 with x63 water 9 
immersion lens (HC PL APO 63x/1.20W CORR CS2; BAM, LabB), and a Leica SP2 with x63 10 
water lens (HCX APO L 63x/0.9W; Groningen, LabC) for 3 biological repeats comprising 3 11 
technical repeats per site (n=9 biological / n=27 technical). Z-stacks (1 μm) were taken of the 12 
biofilms formed on the PDMS surface of the device at five separate regions (beside the inlet, 13 
25%, 50%, 75%, and beside the outlet). COMSTAT 2.1 (Image J) analysis of combined 14 
confocal data was performed to provide a quantification of average biofilm thickness and 15 
Live/Dead biovolume 87. A 2-way ANOVA multiple comparison was performed with Tukey’s 16 
post hoc test to determine 95% confidence intervals. Similar conditions were applied to strain 17 
PA4726 (cbrB) that had shown reduced biofilm growth during screening, and PA3552 (arnB) 18 
which demonstrated robust biofilm formation. Biofilm formation of both mutant strains was 19 
compared to the MPAO1 WT strain after 18 h growth in the flow chamber. 20 
 21 
Screening the public MPAO1 transposon library for antibiotic resistance  22 
 23 
The protocol to assess the antibiotic resistance of biofilm-forming MPAO1 cells was adapted 24 
from a previous study 88. Frozen mutant stocks of 95 randomly selected mutants of the UW 25 
Genome Center’s P. aeruginosa PAO1 transposon mutant library 21, each harboring a 26 
transposon insertion inactivating the function of the respective gene, were allowed to recover 27 
in 20% BHI overnight at 150 rpm and 37 °C. All subsequent incubations were done at 37 °C 28 
in 96 well plates (TPP tissue culture 96 well plates, Z707902, Sigma-Aldrich) covered with an 29 
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air-permeable foil (Breathe-Easy sealing membrane, Z380059, Sigma-Aldrich) without further 1 
shaking. The overnight cultures were diluted 10 fold in M9 medium and 100 µL each was 2 
distributed in six plates (1 well/mutant/plate). After 24 h incubation, the biofilm formation from 3 
two plates was quantified by crystal violet staining, while biofilms from the other four plates 4 
were washed with 0.9% NaCl to remove planktonic bacteria. Bacteria were then exposed to 5 
either M9 or M9 supplemented with 25 µg/mL of colistin, i.e., much higher than the minimal 6 
inhibitory concentration (MIC) for planktonic growth of P. aeruginosa (4 µg/mL), allowing us 7 
to focus specifically on the biofilm bacteria. After 24h treatment, the medium was removed, 8 
biofilms were washed with 0.9% NaCl to remove all traces of antibiotics, and bacteria were 9 
allowed to recover in fresh colistin-free M9 medium. After 24 h incubation, the recovery of 10 
biofilm bacteria was measured by turbidity (OD600) to reveal if the mutation influences the 11 
resistance attributed by the biofilm. To confirm the reliability of our screening, promising 12 
mutants were analyzed independently in triplicate. Cell suspensions of each mutant were 13 
prepared in M9 medium (5 x106 CFU/mL) and biofilm biomass was quantified by crystal violet 14 
after 24 h incubation at 37 °C. Biofilm cells resistance was quantified by measuring the 15 
turbidity of biofilm suspension after 24 h treatment with different concentrations of colistin 16 
and after 24 h recovery in fresh M9 medium. Selected mutants of interest were further 17 
characterized to assess biofilm formation (as described above), MIC and MBIC (see 18 
Supplementary Fig. S3 for detail).  19 
 20 
Protein extraction from MPAO1 planktonic and biofilm cultures  21 
 22 
For planktonic protein extractions, 10 mL MPAO1 was grown overnight (~18 h) in M9 23 
medium under gentle rotation (150 rpm), centrifuged at 4,000 xg/5 min/RT, and the pellet 24 
resuspended in 1 mL Hanks’ Balanced Salt Solution (HBSS). Biofilms were grown for 72 h 25 
using the microfluidic device as previously described, the PDMS device removed from the 26 
glass coverslip, and the combined biofilm biomass from 3 lanes harvested into 1 mL HBSS. 27 
Cells from both populations were washed twice in HBSS at 10,000 xg/5 min/RT and the 28 
pellets resuspended in 1 mL lysis buffer (7 M urea, 2 M thiourea, 35 mM CHAPS, 20 mM 29 
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DTT, 1 M NaCl). Samples were frozen at -80 oC for 30 min and then thawed at 34 oC for 20 1 
min. Trichloroacetic acid (TCA) precipitation was performed by adding the bacterial samples 2 
to 100% ice-cold acetone and 100% trichloroacetic acid in a 1:8:1 ratio and precipitating at -3 
20 oC for 1 h. Samples were then centrifuged (18,000 xg/10 min/4 oC), the supernatant 4 
discarded, and the pellet washed twice with 1 mL ice-cold acetone (18,000 xg/10 min/4 oC). 5 
Acetone was removed, the pellet air-dried at room temperature, and resuspended in 0.1 M 6 
Triethylammonium bicarbonate (TEAB) plus 0.1% Rapigest. Protein sample validation was 7 
performed by 1DE gel electrophoresis. 19.5 μL sample was added to 7.5 μL NuPAGE LDS 8 
buffer and 3 μL NuPAGE reducing reagent, heated at 70 oC for 10 min, then run on a 9 
NuPAGE 4-12% Bis-Tris gel with MOPS buffer at 200 V for 50 min alongside a Novex Sharp 10 
standard. The gel was stained with SimplyBlue Safe Stain for 1 h, then destained with dH2O.  11 
 12 
Protein processing, mass spectrometry and database search 13 
 14 
Protein samples were heated at 80 oC for 10 min, then DTT added at a final concentration of 15 
2 mM and incubated at 60 oC for 45 min. Samples were then briefly vortexed, pulse spun, 16 
and cooled to room temperature before adding iodoacetamide to a final concentration of 6 17 
mM. Samples were incubated at room temperature for 45 min (protected from light), vortexed 18 
and pulse spun briefly, then trypsin added at a final concentration of 1.3 µg/mL. Following 19 
incubation overnight at 37 oC (protected from light), trifluoroacetic acid (TFA) was added to a 20 
final concentration of 0.5% then incubated at 37 oC for 30 min. Samples were centrifuged at 21 
13,000 xg for 10 min at RT, the supernatants removed and vacuum concentrated. The 22 
resultant pellets were resuspended in 3% acetonitrile + 0.1% trifluoroacetic acid and peptide 23 
quantification performed using the Direct Detect system (Merck Millipore). Protein samples 24 
were normalized then vacuum concentrated in preparation for mass spectrometry.  25 
Peptide extracts (1 μg on column) were separated on an Ultimate 3000 RSLC nano system 26 
(Thermo Scientific) using a PepMap C18 EASY-Spray LC column, 2 μm particle size, 75 μm 27 
x 75 cm column (Thermo Scientific) over a 140 min (single run) linear gradient of 3–25% 28 
buffer B (0.1% formic acid in acetonitrile (v/v)) in buffer A (0.1% formic acid in water (v/v)) at 29 
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a flow rate of 300 nL/min. Peptides were introduced using an EASY‐Spray source at 2000 V 1 
to a Fusion Tribrid Orbitrap mass spectrometer (Thermo Scientific). The ion transfer tube 2 
temperature was set to 275°C. Full MS spectra were recorded from 300 to 1500 m/z in the 3 
Orbitrap at 120,000 resolution using TopSpeed mode at a cycle time of 3 s. Peptide ions 4 
were isolated using an isolation width of 1.6 amu and trapped at a maximal injection time of 5 
120 ms with an AGC target of 300,000. Higher‐energy collisional dissociation (HCD) 6 
fragmentation was induced at an energy setting of 28 for peptides with a charge state of 2–4. 7 
Fragments were analysed in the Orbitrap at 30,000 resolution. Analysis of raw data was 8 
performed using Proteome Discoverer software (Thermo Scientific) and the data processed 9 
to generate reduced charge state and deisotoped precursor and associated product ion peak 10 
lists. These peak lists were searched against the P. aeruginosa MPAO1 protein database (a 11 
max. of one missed cleavage was allowed for tryptic digestion, variable modification was set 12 
to contain oxidation of methionine and N-terminal protein acetylation, and 13 
carboxyamidomethylation of cysteine was set as a fixed modification). The FDR was 14 
estimated with randomized decoy database searches and was filtered to below 1% FDR at 15 
the protein level. Differentially abundant proteins were identified using DESeq2 89; 16 
significantly differentially abundant proteins had an adjusted (multiple testing corrected) p 17 
value ≤ 0.05 and a log2 fold change of ≥ 1 or ≤ -1. 18 
 19 
Proteogenomics  20 
 21 
An iPtgxDB was created for P. aeruginosa MPAO1 as described previously 31, using the 22 
NCBI annotation as anchor annotation. Ab initio gene predictions from Prodigal 90 and 23 
ChemGenome 91 and a modified in silico prediction that considers alternative start codons 24 
(TTG, GTG, CTG) and ORFs above 6 amino acids (aa) in length were integrated in a step-25 
wise fashion. Proteomics data from MPAO1 cells grown planktonically or as biofilm were 26 
searched against this iPtgxDB with MS-GF+ (v2019.04.18) 92 using Cysteine 27 
carbamidomethylation as fixed, and oxidation of methionine as variable modifications. Using 28 
the target-decoy approach of MS-GF+, the FDR at the PSM level was estimated and filtered 29 
28 
 
below 0.2%. Only unambiguous peptides as identified by a PeptideClassifier analysis 55, 1 
using the extension that supports proteogenomics for prokaryotes 31, were considered. 2 
The article was previously published as a preprint 93.  3 
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Code Availability 1 
 2 
Open source R code used for genomic, Tn-seq and proteomics data processing is available 3 
from the authors upon request. 4 
Data Availability  5 
 6 
The MPAO1 genome sequence is available at NCBI Genbank (acc# CP027857; Bioproject: 7 
PRJNA438597, Biosample: SAMN08722738). Read data are available under SRR10153205 8 
(Illumina) and SRR10153206 (PacBio). Proteomics data are available from PRIDE (acc# 9 
PXD017122) upon acceptance of the manuscript. The iPtgxDBs for P. aeruginosa MPAO1 10 
and PAO1 are available from https://iptgxdb.expasy.org, both as a searchable protein 11 
database (FASTA format) and a GFF file, which can be loaded in a genome viewer and 12 
overlaid with experimental evidence. Biofilm growth data from the microfluidic chamber will 13 
be made available at https://doi.org/10.21253/DMU.c.4851483. To support technology 14 
dissemination, the polyurethane master molds of the microfluidic chambers are available 15 
upon request from the UoS/NBIC; a CAD file can be found as Supplementary Data 5. Code 16 
availability: all analyses presented rely on open source software or published code that is 17 
referenced. 18 
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Figure Legends  1 
 2 
Fig. 1. Genome map of P. aeruginosa MPAO1 and comparison to other strains.  3 
(a) The Circos plot visualizes the comparison of our complete MPAO1 genome (outer circle 4 
with genome coordinates) and that of strain MPAO1/P1 (second circle; blue), the respective 5 
gaps (third circle; blue) followed by annotated prophages (fourth circle; purple), missing 6 
genes (fifth circle, light blue), pseudogenes (sixth circle; brown), and GC skew (seventh 7 
circle; positive - purple; negative - green). (b) Differences of the MPAO1 genome compared 8 
to the PAO1 reference strain. Going from outer towards inner circles, the following genome 9 
features are shown: (1) a large inversion (gray) flanked by rRNAs (not shown), (2) SNPs 10 
(dark orange), (3) INDELs (light orange) (4) prophages (purple), (5) genes unique to MPAO1 11 
(blue). (c) Comparative genomic analysis of P. aeruginosa strains MPAO1 and PAO1-UW. 12 
The Venn diagram shows the core gene clusters (paralogous genes are grouped into the 13 
same cluster provided they belong to a syntenic genomic region) and the respective number 14 
of strain-specific CDS clusters.  15 
 16 
Fig. 2. An overview of annotated genes in selected prophage regions and their essentiality 17 
classification.  18 
MPAO1-unique essential genes are shown in dark blue, general essential MPAO1 genes 19 
with a red arrow outline. (a) Genes located in prophage region 2 of PAO1-UW (gray), the 20 
corresponding inverted region in strain MPAO1 (light blue arrows in middle), and the 21 
prophage region 3 (light blue arrows on top) unique to MPAO1 are shown (not drawn to 22 
scale), the genomic positions of their boundaries (5’ to 3’) and flanking tRNAs. Genes 23 
connected by lines are orthologous to each other based on comparative genomics combined 24 
with a Blast analysis. (b) Transposon insertions in selected genes of prophage region 3 of 25 
MPAO1. Insertion frequencies in six genes are shown using data mapped from the LB-1 (3 26 
replicates), LB-2 (2 replicates) and LB-3 (1 sample) Tn-seq libraries. Non-essential genes 27 
(based on dataset of 577 genes essential in one of three primary growth conditions) are 28 
shown in light blue.  29 
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 1 
Fig. 3. The publicly available mold design for the microfluidic flow chamber allows 2 
reproducible biofilm formation as confirmed by an inter-laboratory comparison.  3 
(a) Schematic and dimensions of the flow chamber. (b) Representative images of 72 h 4 
MPAO1 WT biofilms grown on the PDMS surface of the device under laminar flow conditions 5 
at five different locations along the channel. Biofilms were treated with live/dead staining 6 
(green – live cells stained with Syto9; red – dead cells stained with propidium iodide). Scale 7 
bar in confocal XY plane: 40 µm. Sagittal XZ section represents biofilm thickness. (c) 8 
COMSTAT data for average thickness, and live/dead biovolume of 72 h MPAO1 WT biofilms 9 
generated by three different laboratories, with 95% confidence interval comparisons (3 10 
biological repeats comprising 3 technical repeats per site, i.e., n=9 biological / n=27 technical 11 
repeats overall; error bars - standard error of mean; 2-way ANOVA with lab and channel 12 
location as variables followed by multiple comparisons Tukey test). *p value < 0.05. 13 
 14 
Fig. 4. Proof of principle that biofilm growth-relevant and AMR-related genes can be 15 
identified in adequate screens using the MPAO1 transposon mutant library.  16 
A diagram of the protocol is shown in Supplementary Fig. 3. (a) Biofilm formation of 90 17 
MPAO1 mutant strains (X-axis) after 24h incubation in M9 medium (average of two 18 
independent wells). Biofilm biomass was quantified by crystal violet. (b) Ability of biofilms 19 
formed by 90 MPAO1 mutant strains to recover after colistin treatment (see Methods). The 20 
recovery of treated biofilm cells was normalized to the recovery of non-treated biofilm cells 21 
(defined as 100%). The arnB mutant (PA3552) is highlighted in red, as well as the highest 22 
biofilm former missing pntAA (PA0195) and the lowest biofilm former missing cbrB (PA4726). 23 
 24 
Fig. 5. Confirmation of the phenotypes identified in our screening.  25 
(a) Biofilm formation was quantified after 24h incubation in M9 medium by crystal violet 26 
staining (average of at least 18 wells from two independent cultures). The pslB and retS 27 
mutants were used as a reference for low and high biofilm formation, respectively. The cbrB 28 
and pntAA mutants demonstrated substantially reduced and increased biofilm formation, 29 
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respectively. Symbols (* and §) indicate significant differences (Student's tests with p value < 1 
0.001) in comparison to MPAO1 WT and the arnB mutant, respectively. PAO1 genes are 2 
shown in brackets, the respective MPAO1 genes are mentioned in the text. (b) Resistance of 3 
planktonic and biofilm cells towards colistin was evaluated for a subset of mutant strains 4 
identified in the screening (1) or based on differential proteomics abundance (2). The MIC was 5 
determined as the lowest concentration resulting in 90% reduction of bacterial growth after 6 
24h in M9 medium compared to the non-treated condition (average of four replicates from 7 
two independent cultures). The MBIC was determined as the lowest concentration resulting 8 
in 50% or 90% reduction of the biofilm cells recovery after 24h treatment compared to the 9 
non-treated condition (average of four replicates from two independent cultures). (c) 10 
Comparative confocal micrographs after live/dead staining (green – live cells stained with 11 
Syto9; red – dead cells stained with propidium iodide) of 18 h MPAO1 WT, cbrB and arnB 12 
biofilms grown under microfluidic conditions using the publicly available mold confirm 13 
reduced biofilm formation for the cbrB mutant and robust biofilm formation of the arnB mutant 14 
in the absence of treatment. 15 
 16 
Fig. 6. Proteomic experiments identify known biofilm-related proteins and new information. 17 
(a) Differential protein abundance between MPAO1 mid-exponential planktonic cells and 72 18 
h biofilms. Selected significantly upregulated proteins (red dots) known to play a role in 19 
biofilm formation/growth are labeled, proteins downregulated in planktonic growth are shown 20 
in blue. Red triangles denote proteins encoded by genes missed in the MPAO1/P1 genome. 21 
(b) Proteogenomic expression evidence for a longer protein than annotated by RefSeq: the 22 
Prodigal predicted protein MPAO1prod_16460 (gray arrow; 447 aa; amino acid) is 44 aa 23 
longer than the RefSeq annotated MPAO1_08365 and encodes a glutamine synthetase (blue 24 
arrow; 413 aa). The NH-terminal extension is supported by 1 peptide (red) with seven PSMs 25 
and harbors a 40 aa longer glutamine synthetase N-terminal domain compared to the 26 
RefSeq protein. (c) Proteogenomic expression evidence for a single nucleotide insertion 27 
(red) in the MPAO1_25975 gene (blue arrow) compared to its PAO1 homolog PA4875 28 
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(annotated as pseudogene; gray open arrow). The change is supported by peptide evidence 1 
(1 red bar).  2 
 3 
Fig. 7. Integrated model system to identify and validate genes relevant for biofilm growth and 4 
AMR.  5 
A sequential genomics-driven workflow (blue arrows) to de novo assemble the complete 6 
genome, identify unique and conserved genes among key reference strains by comparative 7 
genomics and missed genes by proteogenomics is integrated with an experimental workflow 8 
in the form of an iterative cycle that can be entered at various points (yellow arrows). This 9 
workflow allows the study of biofilm grown cells, to explore differentially abundant genes or 10 
proteins compared to planktonic cells and to screen mutant libraries to identify functionally 11 
relevant genes. The model leverages the enormous value of genetic resources like gene 12 
knockout or transposon insertion mutant libraries and functional genomics datasets (RNA-13 
seq, Tn-seq, etc.; blue containers). Additionally, it allows for phenotypic characterization of 14 
biofilms formed by mutant strains, thereby allowing us to determine the impact of specific 15 
genes on biofilm formation and assess their role in AMR (yellow arrows). 16 
 17 
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Table 1. Summary over core and strain-specific CDS of strains MPAO1 and PAO1-UW.  
*All individual CDS are shown including those that are grouped in gene clusters (paralogs) in 
Fig. 1c. **CDS of 120 bp or below are not considered (see Methods). 
 
 
 Category 
P. aeruginosa 
MPAO1 
P. aeruginosa 
PAO1-UW 
Total No. of genes 5,926 5,697 
Total No. of CDSs 5,799 5,572 
No. of core CDSs (clusters*) 5,548 (5,534) 5,545 (5,534) 
No. of unique (strain-specific) CDSs (clusters) 234 (232) 19 (21) 
Unique ncRNA - 3 
CDSs ≤ 120 bp** 17 5 
 
 
Table 2. List of 18 selected MPAO1-unique genes along with their essentiality classification 
in all 16 Tn-seq samples 24 and comments about their genomic location. Information about all 
MPAO1-unique essential genes is available in Supplementary Data 4. 
 
Locus Gene annotation 
General 
essential
Essential in 
x/16 
samples 
Comment 
MPAO1_22380 
type II toxin-antitoxin system 
Phd/YefM family antitoxin 
yes 16 Prophage 2 
MPAO1_00215 hypothetical protein yes 15 *Operon? 
MPAO1_10410 hypothetical protein yes 14 
MPAO1_22450 DNA-binding protein yes 14 Prophage 2 
MPAO1_25260 cytidine deaminase 12 
MPAO1_12950 hypothetical protein yes 11 
MPAO1_00230 hypothetical protein 10 *Operon? 
MPAO1_20095 hypothetical protein 10 
MPAO1_02335 dihydropyrimidinase 9 
MPAO1_15010 
6-O-methylguanine DNA 
methyltransferase  
9 
 
MPAO1_15215 amino acid permease 9 
MPAO1_18025 ferredoxin 9 
MPAO1_02315 oxidoreductase 8 
MPAO1_05695 hypothetical protein yes 8 Bacteriocin (GO)
MPAO1_08710 DUF3304 domain-containing protein 8 
MPAO1_10195 universal stress protein 8 
MPAO1_14380 glycosyltransferase 8 
MPAO1_24865 hypothetical protein 8 Prophage 3 
 
 
Table 3. List of 61 proteins with significant differential abundance (see text) or unique 
expression when comparing biofilm grown and planktonic cells.  
Publications linking the genes/proteins with various roles in biofilms are listed for proteins 
highlighted in Fig. 6. Two genes missed in MPAO1/P1 are shown in bold. Gene names stem 
from the National Center for Biotechnology Information (NCBI) annotation, or were deduced 
from the eggNOG annotation or the respective PAO1 homolog (*) or the Pseudomonas 
genome database (**); see also Supplementary Data 1. 
 
 
Locus tag gene product 
log2 
FC 
 
padj 
Comment, 
Reference
Biofilm only    
MPAO1_19985 napA Nitrate reductase catalytic subunit NapA 5.02  0.05   
MPAO1_04195   SH3 domain-containing protein 5.02  0.05   
MPAO1_10705   Methyl-accepting chemotaxis protein 5.11  0.03   
MPAO1_17160   
EscC/YscC/HrcC family type III secretion system 
outer membrane ring protein 
5.11  0.03   
MPAO1_21585   Itaconyl-CoA hydratase 5.19  0.04   
MPAO1_17195   Translocator outer membrane protein PopD 5.19  0.02   
MPAO1_17200   Hypothetical protein 5.34  0.01   
MPAO1_00520 vgrG1b* Type VI secretion system tip protein VgrG1b 52 5.41  0.01 H1-T6SS 44
MPAO1_20935   Beta-keto-ACP synthase 5.61  0.04   
MPAO1_24325   Cytochrome c551 peroxidase 6.11  0.00   
Diff. Abundant    
MPAO1_07815   
Osmoprotectant NAGGN system M42 family 
peptidase 
4.70  0.02   
MPAO1_19625 aprX Hypothetical protein 5.45  0.00 45 
MPAO1_24535 cdrA*  Filamentous hemagglutinin N-terminal domain-
containing protein 
6.54  0.00 50 
MPAO1_02725 nirF Protein NirF 4.30  0.01 
MPAO1_24530 cdrB* ShlB/FhaC/HecB family hemolysin 
secretion/activation protein
4.35  0.01 50 
MPAO1_25250   BON domain-containing protein 3.28  0.05   
MPAO1_19595   Serralysin 3.75  0.01   
MPAO1_22090 putA Bifunctional proline dehydrogenase/L-glutamate 
gamma-semialdehyde dehydrogenase PutA 
3.00  0.01   
MPAO1_18330  muiA* Mucoidy inhibitor MuiA 2.69  0.01  46 
MPAO1_21730 cbpD*  Chitin-binding protein CbpD 2.79  0.00  47 
MPAO1_06120   Copper chaperone PCu(A)C 1.98  0.03   
MPAO1_14990   NAD(P)-dependent alcohol dehydrogenase 2.22  0.01   
MPAO1_02740 nirS  Nitrite reductase 2.52  0.00   
MPAO1_25230   DUF748 domain-containing protein 1.85  0.02   
MPAO1_18000 ccoP Cytochrome-c oxidase, cbb3-type subunit III 1.60  0.05   
MPAO1_28880 adhP Alcohol dehydrogenase AdhP 2.52  0.00   
MPAO1_07010   Phosphoketolase 2.07  0.00   
MPAO1_00100   
LysM peptidoglycan-binding domain-containing 
protein 
1.44  0.03   
MPAO1_02290   TonB-dependent receptor 1.66  0.01   
MPAO1_27435   Amino acid ABC transporter substrate-binding protein -3.09  0.03   
MPAO1_05385   DUF1302 domain-containing protein -2.80  0.03   
MPAO1_17965 acnA*  Aconitate hydratase 1.49  0.01  48 
MPAO1_24155 pilY1*  Type 4a pilus biogenesis protein PilY1 1.54  0.01  49 
MPAO1_05375   Fatty acid--CoA ligase -5.06  0.01   
MPAO1_04650   OmpW family protein 1.49  0.01   
MPAO1_00495 tssH Type VI secretion system ATPase TssH 1.27  0.03  H1-T6SS 
 44 
MPAO1_14010   Non-ribosomal peptide synthetase (NRPS) 1.90  0.02   
MPAO1_26210 azu Azurin 2.45  0   
MPAO1_13620   
Xanthine dehydrogenase family protein 
molybdopterin-binding subunit 
-4.33  0.01   
MPAO1_03800  pchA Salicylate biosynthesis isochorismate synthase -3.04  0.01   
MPAO1_06095   TonB-dependent copper receptor 1.74  0.00   
MPAO1_03775   Catalase 1.67  0.00   
MPAO1_02430 clpG AAA family protein disaggregase ClpG 2.31  0.00   
MPAO1_26945   
Poly(3-hydroxyalkanoate) granule-associated protein 
PhaF 
1.22  0.03   
MPAO1_23990   
Prepilin-type cleavage/methylation domain-containing 
protein 
3.01  0.00   
MPAO1_02180   Response regulator 1.13  0.00   
MPAO1_05390   DUF1329 domain-containing protein -2.62  0.00   
MPAO1_13900   
NADP-dependent glyceraldehyde-3-phosphate 
dehydrogenase 
-1.11  0.05   
MPAO1_13035   
Multidrug efflux RND transporter periplasmic adaptor 
subunit MexE 
-1.92  0.00   
MPAO1_25100   
TonB-dependent hemoglobin/transferrin/lactoferrin 
family receptor 
-1.17  0.02   
MPAO1_09260   
Carbohydrate ABC transporter substrate-binding 
protein 
-0.99  0.02   
MPAO1_16835   Porin 1.34  0.00   
MPAO1_09280   Porin -1.54  0.00   
Planktonic only    
MPAO1_23930 puiA** TonB-dependent siderophore receptor -6.91  0.00   
MPAO1_22860 pctC  Methyl-accepting chemotaxis protein PctC -6.78  0.00   
MPAO1_07425 argF Ornithine carbamoyltransferase -5.51  0.01   
MPAO1_21260   Chain-length determining protein -5.22  0.02   
MPAO1_15475   Siderophore-interacting protein -5.09  0.02   
MPAO1_29055   Class I SAM-dependent methyltransferase -5.08  0.03   
MPAO1_22680   Biliverdin-producing heme oxygenase -5.02  0.03   
MPAO1_09305 pgl 6-phosphogluconolactonase -5.01  0.03   
 
 
